We are not doctors. We are advocates.Nothing on this site constitutes medical advice.

← TherapiesHEALTH AND RESEARCH

Is Leucovorin Approved for Autism? A Plain-English Update for Parents

Leucovorin has drawn wide attention since federal health officials discussed it in connection with autism in September 2025. This page sets out what the FDA actually approved, what happened to the research, and what that means for coverage, without hype and without judgment for any family's choice.

WeBearish mascot bear
QUICK ANSWER

Is leucovorin approved for autism?

No. In March 2026 the FDA approved leucovorin tablets to treat cerebral folate transport deficiency in children and adults who have a confirmed variant in the FOLR1 gene, a rare genetic condition, and the label does not list autism. A major 2024 trial of the drug in autistic children was retracted in January 2026, so talk with your child's doctor before starting, stopping, or changing it.

Last reviewed:

What Leucovorin Is

Leucovorin, also called folinic acid, is a form of folate, the B vitamin. It is not new: its FDA label lists an initial U.S. approval in 1952. Its other labeled uses are reducing the toxic effects of the drug methotrexate in adults whose bodies clear it too slowly, and treating overdoses of certain folate-blocking drugs in adults. GSK sold it under the brand name Wellcovorin from 1983 to 1997, and today it is sold in the United States as a generic.

Interest in autism comes from research on folate and the brain. The American Academy of Pediatrics (AAP) describes cerebral folate deficiency as low levels of an active form of folate in the fluid around the brain and spinal cord, notes that autism can be one of its features, and lists causes that include FOLR1 gene variants and antibodies to the folate receptor. That overlap is why researchers studied leucovorin, and why the details of who might benefit matter so much.

What the Label Covers, and What It Does Not

On March 10, 2026, the FDA announced approval of Wellcovorin (leucovorin calcium) tablets for a new use. The updated label is specific:

What it covers
Treatment of cerebral folate transport deficiency in adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene, written on the label as FOLR1-CFTD. The FDA describes this as a rare genetic neurological condition in which folate is not transported into the brain properly, and says people with it often have severe developmental delays, movement disorders, and seizures.
What it does not cover
Autism. The label does not list autism as an indication. At the time of approval, an FDA official told reporters the agency did not have sufficient data to establish effectiveness for autism more broadly.
How the approval was made
No clinical trials have been run in FOLR1-CFTD. The label says the evidence came from the published literature: 46 patients described in 26 case reports and case reviews through 2024. The FDA also cited mechanistic data.
Who should not use it
The label says it is not recommended for people with a deficiency of an enzyme called MTHFS. For FOLR1-CFTD, it should not be used by people with a history of any hypersensitivity (allergic) reaction to leucovorin, levoleucovorin, folic acid, or any ingredient in the tablets.

FDA Commissioner Marty Makary said the action may benefit some people with FOLR1-related cerebral folate transport deficiency who have developmental delays with autistic features. That describes a subset of people with a confirmed genetic diagnosis, not autistic children in general. The FDA says health care providers generally may prescribe an approved drug for an unapproved use, called off-label use, and in that case the FDA has not reviewed whether the use is safe and effective. Whether that makes sense for your child is a decision to make with your child's doctor.

The Research and the Retraction

Research on leucovorin in autism is still early. The AAP notes that small studies suggest benefits to communication and behavior in some autistic children, mainly those with cerebral folate deficiency or folate metabolism differences, but that the studies have all included fewer than 100 patients and no large, multicenter phase 3 trial has been done. Here is where things stand:

→
The 2024 trial: In September 2024 the European Journal of Pediatrics published a randomized, placebo-controlled trial of oral folinic acid in 80 autistic children ages 2 to 10, run at AIIMS Rishikesh in India. It reported improvements in the folinic acid group. The Transmitter, an autism research news outlet, described it as the largest trial of its kind.
→
The retraction: On January 29, 2026, the journal published a retraction note. It says concerns were raised about the data, including apparent errors in the results tables and problems with the statistical analyses. A statistical review after publication confirmed several concerns and could not reproduce the reported results from the dataset the authors provided, and the editor said they no longer had confidence in the validity of the results and conclusions.
→
What the retraction means: A retraction means the published results can no longer be relied on. It does not by itself show whether leucovorin helps or harms. The note says two of the six authors agreed with the retraction and the other four did not respond.
→
The AAP position: The AAP says current evidence is insufficient to support prescribing leucovorin for autism in the absence of cerebral folate deficiency, and it asks pediatricians to use shared decision-making with families who request it.

If your family tried leucovorin or is thinking about it, that was a reasonable thing to ask about with the information you had. Wanting to help your child is never the wrong instinct. For more plain-language summaries, see our autism research page, and for the background on how the 2025 announcements changed prescribing, see our post on the FDA label and what it does not cover.

Insurance and Medicaid Coverage

Coverage for leucovorin prescribed for autism varies by state and by plan. These are the facts we could confirm:

→Federal Medicaid law lets states require prior authorization for any covered outpatient drug, and lets them exclude or restrict coverage when a drug is prescribed for a use that is not a "medically accepted indication."
→The law defines a medically accepted indication as a use approved by the FDA, or a use supported by citations in certain recognized drug reference books called compendia.
→Because autism is not on the label, whether Medicaid pays for an autism-related prescription depends on how each state and its managed care plans apply these rules.
→In September 2025, federal health officials said state Medicaid programs would be able to cover leucovorin for autism after a label update. The label that was approved in March 2026 does not include autism.
→As of late October 2026, CMS had not issued guidance requiring states to cover leucovorin for autism. A CMS spokesperson told Acuity that coverage depends on state policy, medical-necessity criteria, and the drug's FDA-approved indications.
→Testing sometimes used to look for cerebral folate deficiency, such as blood tests for folate receptor antibodies, may not be covered by insurance, according to the AAP.

If you have private insurance, call the number on your card or check your plan's drug list (formulary) and ask whether prior authorization is needed. Your child's doctor's office can often help with the paperwork. Our guide to insurance and autism evaluations covers prior authorization and appeals in more detail.

Questions to Ask Your Child's Doctor

Whether your child already takes leucovorin or you are considering it, these questions can help you have a clear, shared conversation:

→Is there a reason to suspect cerebral folate deficiency in my child, and how would we find out?
→Would genetic testing for a FOLR1 variant make sense, and would a neurologist or geneticist need to be involved?
→What specific changes are we hoping to see, and how will we measure whether they happen?
→What side effects should I watch for? The AAP lists irritability, stomach upset, and skin reactions, and the label warns about allergic reactions.
→Does my child take any seizure medicine? The label calls for closer monitoring of seizure activity when leucovorin is used with certain antiepileptic drugs.
→How long would we try it, and when would we stop if it is not helping? The AAP says how long children should take it is not yet known.
→Will insurance or Medicaid cover it for my child, and will it need prior authorization?
→If my child already takes it, should anything change now that the 2024 trial has been retracted?

Leucovorin is one question among many. Our therapies guide covers other supports, such as speech and occupational therapy, and what the evidence and autistic people say about them.

This is not medical advice. WeBearish is an autism acceptance movement built by parents, not a medical provider. This page explains public information as of November 2, 2026. Please do not start, stop, or change any medicine for your child without talking to their doctor.

Sources

Frequently Asked Questions

Is leucovorin FDA approved for autism?

No. In March 2026 the FDA approved Wellcovorin (leucovorin calcium) tablets for cerebral folate transport deficiency in people with a confirmed FOLR1 gene variant. The label does not list autism, and FDA officials said the data were not sufficient to establish effectiveness for autism more broadly.

What is cerebral folate transport deficiency?

It is a rare genetic neurological condition in which folate, a vitamin important for brain health, is not carried into the brain properly. The FDA says people with the FOLR1 form often have severe developmental delays, movement disorders, and seizures.

Why was the leucovorin autism trial retracted?

In January 2026 the European Journal of Pediatrics retracted a 2024 trial of oral folinic acid in autistic children. A statistical review confirmed concerns about the data and could not reproduce the reported results, so the editor no longer had confidence in its conclusions.

Will Medicaid or insurance cover leucovorin for autism?

It depends on your state and your plan. Federal law lets state Medicaid programs restrict drugs prescribed for uses that are not medically accepted indications and require prior authorization. Autism is not on the label, and CMS has not required states to cover it for autism.

My child already takes leucovorin. Should we stop?

Do not stop or change it on your own. Talk with the doctor who prescribed it about why it was started, what changes you have seen, and whether to continue. The American Academy of Pediatrics says how long children should take it is not known.

We are not doctors. We are advocates. Nothing on this site constitutes medical advice. Always consult a qualified healthcare provider about diagnosis, treatment, or any decision regarding your health or your child's health.

RELATED ON WEBEARISH